Trial Profile
DFN-02 Open Label Safety Study in Patients With Acute Migraine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jul 2020
Price :
$35
*
At a glance
- Drugs Sumatriptan (Primary)
- Indications Migraine; Migraine with aura; Migraine without aura
- Focus Adverse reactions; Registrational
- Sponsors Dr Reddys Laboratories
- 20 Jun 2020 Results presented at the 62nd Annual Scientific Meeting of the American Headache Society.
- 07 Jul 2016 Status changed from active, no longer recruiting to completed.
- 08 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Mar 2016 as per ClinicalTrials.gov record.